La cadena de opciones muestra datos clave de las opciones de acciones de KYB CORP by KYB CORP. a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para KYB CORP by KYB CORP...

KYB CORP by KYB CORP. (OTC:KYBIF) Bolsa, Cadena de Opciones

KYB Corp is a Japanese automobile equipment manufacturer. The company products are divided into three branches hydraulic components (HC), automotive components (AC) and others. Through its operating segments, it provides various products such as shock absorber, suspension system, power steering, motion simulators, front fork and oil cushion unit, tunnel borers, vane pump and electronic parts. It also provides concrete mixer trucks, granule carriers, chipping vehicle and special function vehicles. The majority of the sales are accounted from the AC and HC products.

KYB CORP by KYB CORP.

Citigroup analyst Christopher Allen maintains Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Buy and lowers the price target from $30 to $23.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Blue Owl Capital, Lowers Price Target to $23

Across the recent three months, 14 analysts have shared their insights on Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Academy Sports, revealing an average target of $59.0, a high estimate of $70.00, and a low estimate of $53.00. Observing a downward trend, the current average is 6.78% lower than the prior average price target of $63.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146076_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Academy Sports. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Chukumba &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$77.00 &#x7C; 
&#x7C;Greg Melich &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $53.00&#x7C;$54.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $54.00&#x7C;$52.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$55.00 &#x7C; 
&#x7C;Brian Nagel &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $70.00&#x7C;$85.00 &#x7C; 
&#x7C;Seth Basham &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Anna Glaessgen &#x7C;B. Riley Securities &#x7C;Lowers &#x7C;Buy &#x7C; $65.00&#x7C;$70.00 &#x7C; 
&#x7C;Justin Kleber &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $55.00&#x7C;$60.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $55.00&#x7C;$58.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Academy Sports. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Academy Sports compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Academy Sports's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Academy Sports's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Academy Sports analyst ratings.</a>
<h2>Unveiling the Story Behind Academy Sports</h2>
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports &amp; recreation, and footwear.
<h3>Academy Sports: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Academy Sports's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -6.57% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Academy Sports's net margin excels beyond industry benchmarks, reaching 7.97%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Academy Sports's ROE stands out, surpassing industry averages. With an impressive ROE of 6.74%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.67%, the company showcases effective utilization of assets.
Debt Management: Academy Sports's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.89.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Academy Sports In The Eyes Of 14 Experts

In the latest quarter, 13 analysts provided ratings for Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high estimate of $75.00, and a low estimate of $42.00. A 2.54% drop is evident in the current average compared to the previous average price target of $59.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146066_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Harmony Biosciences Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $70.00&#x7C;$70.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Graig Suvannavejh &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $44.00&#x7C;$42.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Graig Suvannavejh &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $42.00&#x7C;$52.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$52.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $55.00&#x7C;- &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Patrick Trucchio &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $52.00&#x7C;$52.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harmony Biosciences Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Harmony Biosciences Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harmony Biosciences Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Harmony Biosciences Hldgs Better</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
<h3>Harmony Biosciences Hldgs: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Harmony Biosciences Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.51% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Harmony Biosciences Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 24.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Harmony Biosciences Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 7.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Harmony Biosciences Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.13%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.27, Harmony Biosciences Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views

Across the recent three months, 9 analysts have shared their insights on Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Owens-Corning, presenting an average target of $202.44, a high estimate of $235.00, and a low estimate of $176.00. This current average represents a 9.06% decrease from the previous average price target of $222.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146059_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Owens-Corning. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Bouley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $179.00&#x7C;$215.00 &#x7C; 
&#x7C;Collin Verron &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $183.00&#x7C;- &#x7C; 
&#x7C;Mike Dahl &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $212.00&#x7C;$212.00 &#x7C; 
&#x7C;Michael Rehaut &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $176.00&#x7C;$200.00 &#x7C; 
&#x7C;Matthew Bouley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $215.00&#x7C;$245.00 &#x7C; 
&#x7C;Mike Dahl &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $212.00&#x7C;$224.00 &#x7C; 
&#x7C;John Lovallo &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $235.00&#x7C;$245.00 &#x7C; 
&#x7C;Sam Reid &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $200.00&#x7C;$225.00 &#x7C; 
&#x7C;Garik Shmois &#x7C;Loop Capital &#x7C;Lowers &#x7C;Buy &#x7C; $210.00&#x7C;$215.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Owens-Corning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Owens-Corning compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Owens-Corning's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Owens-Corning's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Owens-Corning analyst ratings.</a>
<h2>Unveiling the Story Behind Owens-Corning</h2>
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with four reportable segments: Composites, Insulation, Doors, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
<h3>Owens-Corning: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Owens-Corning's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 23.26%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Owens-Corning's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -9.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Owens-Corning's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -4.82%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Owens-Corning's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.77%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.11, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Owens-Corning's Future

During the last three months, 10 analysts shared their evaluations of GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for GXO Logistics, revealing an average target of $50.5, a high estimate of $66.00, and a low estimate of $40.00. A decline of 19.52% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146050_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive GXO Logistics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ariel Rosa &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $45.00&#x7C;$51.00 &#x7C; 
&#x7C;Lucas Servera &#x7C;Truist Securities &#x7C;Announces &#x7C;Hold &#x7C; $40.00&#x7C;- &#x7C; 
&#x7C;Scott Schneeberger &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $55.00&#x7C;$67.00 &#x7C; 
&#x7C;Thomas Wadewitz &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$72.00 &#x7C; 
&#x7C;Christian Wetherbee &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $44.00&#x7C;$60.00 &#x7C; 
&#x7C;J. Bruce Chan &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $66.00&#x7C;$74.00 &#x7C; 
&#x7C;Ravi Shanker &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$63.00 &#x7C; 
&#x7C;Brandon Oglenski &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $45.00&#x7C;$52.00 &#x7C; 
&#x7C;Rick Paterson &#x7C;Loop Capital &#x7C;Announces &#x7C;Hold &#x7C; $49.00&#x7C;- &#x7C; 
&#x7C;Patrick Creuset &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $54.00&#x7C;$63.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GXO Logistics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GXO Logistics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GXO Logistics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GXO Logistics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GXO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GXO Logistics analyst ratings.</a>
<h2>Delving into GXO Logistics's Background</h2>
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
<h3>Understanding the Numbers: GXO Logistics's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining GXO Logistics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.48% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): GXO Logistics's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.72, GXO Logistics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: GXO Logistics Through The Eyes Of 10 Analysts

24 analysts have expressed a variety of opinions on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $134.75, a high estimate of $155.00, and a low estimate of $82.00. A 6.29% drop is evident in the current average compared to the previous average price target of $143.79. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146037_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Target by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Scot Ciccarelli &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $82.00&#x7C;$124.00 &#x7C; 
&#x7C;Greg Melich &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $120.00&#x7C;$130.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $120.00&#x7C;$130.00 &#x7C; 
&#x7C;Rupesh Parikh &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $150.00&#x7C;$165.00 &#x7C; 
&#x7C;Edward Kelly &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $135.00&#x7C;$150.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $155.00&#x7C;$170.00 &#x7C; 
&#x7C;Robert Ohmes &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $145.00&#x7C;$160.00 &#x7C; 
&#x7C;Scot Ciccarelli &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $124.00&#x7C;$134.00 &#x7C; 
&#x7C;Kate McShane &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $142.00&#x7C;$166.00 &#x7C; 
&#x7C;Bill Kirk &#x7C;Roth MKM &#x7C;Lowers &#x7C;Neutral &#x7C; $122.00&#x7C;$131.00 &#x7C; 
&#x7C;Michael Baker &#x7C;DA Davidson &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$153.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $120.00&#x7C;$133.00 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $124.00&#x7C;$132.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $130.00&#x7C;$145.00 &#x7C; 
&#x7C;Greg Melich &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $130.00&#x7C;$135.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $140.00&#x7C;$146.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Outperform &#x7C; $145.00&#x7C;$150.00 &#x7C; 
&#x7C;Corey Tarlowe &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$165.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $146.00&#x7C;$139.00 &#x7C; 
&#x7C;Zhihan Ma &#x7C;Bernstein &#x7C;Raises &#x7C;Market Perform &#x7C; $142.00&#x7C;$139.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $155.00&#x7C;$145.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $133.00&#x7C;$130.00 &#x7C; 
&#x7C;Scot Ciccarelli &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $134.00&#x7C;$129.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $150.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Target. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Target compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Target's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Target's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TGT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Target analyst ratings.</a>
<h2>Unveiling the Story Behind Target</h2>
Target serves as the nation's seventh-largest retailer, with its strategy predicated on delivering a gratifying in-store shopping experience and a wide product assortment of trendy apparel, home goods, and household essentials at competitive prices. Target's upscale and stylish image began to carry national merit in the 1990s—a decade in which the brand saw its top line grow threefold to almost $30 billion—and has since cemented itself as a leading US retailer.Today, Target operates over 1,900 stores in the United States, generates over $100 billion in sales, and fulfills over 2 billion customer orders annually. The firm's vast footprint is typically concentrated in urban and suburban markets as the firm seeks to attract a more affluent consumer base.
<h3>Target: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Target faced challenges, resulting in a decline of approximately -3.15% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Target's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Target's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.36, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 24 Analysts Discuss Target Stock

Throughout the last three months, 4 analysts have evaluated BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $43.0, a high estimate of $50.00, and a low estimate of $38.00. Highlighting a 1.71% decrease, the current average has fallen from the previous average price target of $43.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744146027_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive BankUnited is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $38.00&#x7C;$44.00 &#x7C; 
&#x7C;Stephen Scouten &#x7C;Piper Sandler &#x7C;Maintains &#x7C;Overweight &#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Karl Shepard &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $43.00&#x7C;$42.00 &#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $50.00&#x7C;$48.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BankUnited. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BankUnited compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of BankUnited's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of BankUnited's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BKU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BankUnited analyst ratings.</a>
<h2>Discovering BankUnited: A Closer Look</h2>
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
<h3>BankUnited: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, BankUnited showcased positive performance, achieving a revenue growth rate of 12.87% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: BankUnited's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 25.51%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): BankUnited's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): BankUnited's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: BankUnited's debt-to-equity ratio stands notably higher than the industry average, reaching 1.29. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down BankUnited: 4 Analysts Share Their Views

In the current session, Danaos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) is trading at $66.47, after a 3.58% drop. Over the past month, the stock fell by 17.30%, and in the past year, by 9.12%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744146027_0_0.png" alt="Past Year Chart" />

<h3>A Look at Danaos P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 16.17 in the Marine Transportation industry, Danaos Inc. has a lower P/E ratio of 2.65. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744146027_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Danaos

Cal-Maine Foods Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) shares are trading lower in Tuesday&#8217;s after-hours session after the company reported third-quarter financial results and announced plans to <a href="https://www.benzinga.com/pressreleases/25/04/b44700699/cal-maine-foods-reports-financial-and-operational-results-for-third-quarter-fiscal-2025-and-announ">acquire Echo Lake Foods</a>.
Q3 Earnings: Cal-Maine reported fiscal third-quarter revenue of $1.42 billion, missing analyst estimates of $1.43 billion, according to&nbsp;<a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The egg producer reported third-quarter earnings of $10.38 per share, beating analyst estimates of $7.93 per share. 
Cal-Maine reported a 14% year-over-year increase in the average number of layer hens during the quarter. The company also reported a 33% increase in breeder flocks and a 24% increase in total chicks hatched during the quarter.
Cal-Maine&#8217;s board approved a $500 million share repurchase program during the third quarter and declared a cash dividend of approximately $3.46 per share.
Don&#8217;t Miss: <a href="https://in.benzinga.com/markets/25/03/44449091/trump-claims-egg-prices-are-way-down-as-us-plans-imports-from-turkey-and-south-korea">Trump Claims Egg Prices Are &#8216;WAY DOWN&#8217; As US Plans Imports From Turkey and South Korea</a>
&#8220;Dynamic market conditions and HPAI-related supply shortages persisted this quarter. However, the entire Cal-Maine Foods team did an outstanding job in maximizing production through a period of high demand, while operating safely and maintaining diligence on biosecurity measures,&#8221; said Sherman Miller, president and CEO of Cal-Maine Foods.
&#8220;We were fortunate to have the ability to utilize our existing operational scale and to benefit from recent acquisitions, which helped increase our production capacity in this challenging supply environment.&#8221;
In addition to earnings, Cal-Maine announced that it signed a definitive agreement to acquire Echo Lake Foods for approximately&nbsp;$258 million. Echo Lake Foods produces ready-to-eat egg products and breakfast foods.
The transaction has been approved by both companies&#8217; boards and is expected to close by the end of fiscal 2025. 
CALM Price Action: <a href="http://benzinga.com/quote/calm">Cal-Maine shares</a> were down 4.57% after-hours, trading at $86.20 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/government/regulations/25/04/44701436/trump-unleashes-beautiful-clean-coal-policies-as-wall-street-tanks-sp-500-hits-1-year-low"> • Trump Unleashes &#8216;Beautiful Clean Coal&#8217; Policies As Wall Street Tanks, S&amp;P 500 Hits 1-Year Low</a>
Photo: Courtesy of Cal-Maine Foods.

After-Hours Center

Movers

CALM

Cal-Maine Foods Stock Cracks After Egg Producer Reports Q3 Results, Inks Deal To Acquire Echo Lake Foods

Citigroup analyst Ariel Rosa maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and lowers the price target from $148 to $113.

Citigroup Maintains Buy on XPO, Lowers Price Target to $113

Citigroup analyst Ariel Rosa maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $149 to $123.

Citigroup Maintains Buy on United Parcel Service, Lowers Price Target to $123

&nbsp;
First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation
In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points and clinical efficacy measures. The primary endpoint, GBS-Disability Scale (DS), showed that after a single infusion of tanruprubart at 30 mg/kg dose, patients had a statistically significant 2.4-fold higher likelihood of being in a better state of health than placebo at Week 8 (p=0.0058).
Highlights from the oral presentation at AAN include:
<ul>
<li>New efficacy findings consistently demonstrated rapid recovery and durable benefits of tanruprubart across muscle strength, mobility and disability measures:
	&nbsp;
<ul>
<li>At Week 1, treated patients rapidly gained motor function and were 14-fold more likely to perform the Timed Up and Go (TUG) test, a standardized measure of mobility, balance and lower limb capacity
		&nbsp;</li>
<li>At Week 1, treated patients rapidly gained motor ability and showed more than a 2-point improvement on the Overall Neuropathy Limitation Scale (ONLS), a tool used to assess limitations in everyday activities of the upper and lower limbs
		&nbsp;</li>
</ul>
</li>
<li>New efficacy findings at Week 26 also demonstrated that the benefit of tanruprubart was durable, with twice the number of treated patients having no limitations on the ONLS compared to placebo 
	&nbsp;</li>
<li>The new findings build upon previously reported Phase 3 trial results that showed an improvement in the primary endpoint of GBS-DS at Week 8, as well as that twice the number of patients treated with tanruprubart fully recovered to normal (GBS-DS = 0) at Week 26, compared to placebo</li>
<li>Treatment with tanruprubart enabled patients to walk independently and be off ventilation (for those requiring it) approximately a month earlier 
	&nbsp;</li>
<li>Patients treated with tanruprubart also spent approximately a week less time in intensive care 
	&nbsp;</li>
<li>Tanruprubart was well tolerated, with no new safety signals or off-target effects&nbsp;&nbsp; 
	&nbsp;</li>
</ul>
Results of the Phase 3 trial are reinforced by a <a href="https://www.globenewswire.com/Tracker?data=DxAw4ku8cSbOSU8IpAbXSnQebYzOh3uqzn1O3X3DAQ9QupIsKD0oAQjbOyBdFTXfJaxflqrBl2gQtSgQEk4RZro0rXvfA_-eHFpk0HFzz80uO8NLXCzlKFXU3MbdyLsggV9qslnoTuGnn5dHLlx2AgLjBz-Ku1vmrFfFjlbIDe39jle2tfy5ITlJtuumWrThfj1vKBZ9DQQxzjisskKZIDLbcSA6S0DNe9mZyc9-SGRHb8yXyks2UOoj4qiYhYjT">Real World Evidence (RWE) study</a>&nbsp;that matched tanruprubart-treated patients from the pivotal Phase 3 study with a Western world patient population treated with current standards of care, intravenous immunoglobulin (IVIg) or plasma exchange (PE). In the RWE study, tanruprubart showed a rapid increase in muscle strength with more complete recovery over IVIg or PE, consistent with benefits shown in the Phase 3 trial.&nbsp;The RWE study is planned for presentation at upcoming conferences.

Biotech

General

ANNX

Annexon Says Tanruprubart Met The Primary Endpoint; Demonstrates Rapid, Durable Recovery and Superior Efficacy In First Placebo-Controlled Phase 3 GBS Trial, Showing Significant Improvement In Motor Function, Mobility, and Disability Measures Over Placebo With No New Safety Signals

WIIM

Peabody Energy shares are trading after President Trump announced he signed an executive order to strengthen the electric grid.

Citigroup analyst Ariel Rosa maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Buy and lowers the price target from $130 to $95.

TFII

Citigroup Maintains Buy on TFI International, Lowers Price Target to $95

Citigroup analyst Ariel Rosa maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $498 to $435.

SAIA

Citigroup Maintains Buy on Saia, Lowers Price Target to $435

<a href="https://www.youtube.com/watch?v=cB6d0H3mSNA">https://www.youtube.com/watch?v=cB6d0H3mSNA</a>

Macro Economic Events

Politics

Economics

Trump Administration Aide Says First Executive Order Will Direct All Agencies To End All Discriminatory Policy Against Coal Industry; Says Trump Signs Executive Order On Coal; Says Second Order Imposes Moratorium That Would Shut Coal Plants; Says Third Order On Grid Reliability; Says Fourth Order Deals With Democratic States That Have Policies Against Coal

Citigroup analyst Ariel Rosa maintains RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) with a Neutral and lowers the price target from $23 to $15.

Citigroup Maintains Neutral on RXO, Lowers Price Target to $15

Citigroup analyst Ariel Rosa maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Buy and lowers the price target from $298 to $259.

Citigroup Maintains Buy on Norfolk Southern, Lowers Price Target to $259

President Donald Trump on Tuesday unveiled sweeping plans to revive U.S. coal production to meet the nation's rising energy demands, marking a dramatic policy reversal from the climate-focused agendas of the Biden <a href="https://www.benzinga.com/topic/donald-trump">and Obama administrations.</a>
Meanwhile, Wall Street plunged deeper into negative territory as escalating tariff tensions with China reignited fears of a global economic slowdown.
"We're ending Joe Biden's war on beautiful clean coal once and for all," Trump declared. "We're going to reopen those plants, put miners back to work, and get approvals very fast."
Trump's order directs federal agencies to fast-track mining permits, slash environmental regulations, and expand coal leases on federal lands.
"Pound for pound, coal is the single most reliable, durable, secure, and powerful form of energy on Earth," the president added.
According to the U.S. Energy Information Administration, coal production in 2023 totaled 578 million short tons, less than half the 1.17 billion short tons produced at its peak in 2008. 
The decline, the EIA noted, has been driven by rising costs, tougher environmental rules, and increased competition from natural gas and renewables.
&#8220;We&#8217;ll be signing a bill to unleash the might of our beautiful clean coal industry in this country,&#8221; Trump said.
Shares of Peabody Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), the largest private-sector coal company in the world, rose 9% in after-hours trading, and Warrior Met Coal Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCC#NYSE">HCC</a>) rose 6.5%.
<h3 class="wp-block-heading">Wall Street Selloff Deepened</h3>
While Trump was touting coal's comeback, Wall Street was in full-blown retreat. 
Major indexes erased hefty morning gains in a volatile session that saw risk sentiment collapse after White House Press Secretary Karoline Leavitt confirmed Trump's 104% retaliatory tariff on Chinese imports would go live at 12:01 a.m. ET Wednesday.
"China made a mistake by retaliating, and the president is punching back harder," Leavitt said, ruling out any delay or exemption to the tariffs.
The news sent a jolt through financial markets, reversing a sharp morning rally and pushing the S&amp;P 500 index to its lowest levels in a year.
The S&amp;P 500 closed at 4,892, down 1.57%, after having surged as much as 3.7% earlier in the session.
The Nasdaq 100 ended the day at 17,104, falling 1.95% from the previous close, despite hitting a 4.1% intraday gain during the morning rally.
The Dow Jones Industrial Average finished at 37,663, shedding 0.8%, after climbing as much as 2.5% at its session peak.
<h3 class="wp-block-heading">Mega-Cap Tech: From Rally To Rout</h3>
Among the Magnificent Seven, losses were led by Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which closed down 5%, falling more than 9 percentage points from its intraday highs. 
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ended 4.9% lower, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) dropped 2.9%. 
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), which had surged more than 3% in morning trading, ended lower by 4%, signaling broad risk aversion toward chipmakers. AI darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) closed 1.4% lower.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44699965/biggest-tax-hike-since-1982-trumps-tariff-strategy-faces-harsh-economic-forecast">Biggest Tax Hike Since 1982? Trump&#8217;s Tariff Strategy Faces Harsh Economic Forecast</a></li>
</ul>
Photo: Shutterstock

Government

Regulations

Econ #s

Tech

AAPL

AMZN

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSLA

Trump Unleashes 'Beautiful Clean Coal' Policies As Wall Street Tanks, S&P 500 Hits 1-Year Low

Citigroup analyst Ariel Rosa maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Buy and lowers the price target from $193 to $164.

Comments

KYB CORP by KYB CORP.

KYB CORP by KYB CORP. (KYBIF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL